Showcase Theatre
The ICNMD 2026 Showcase Theatre features industry-supported presentations highlighting the latest advances, emerging therapies, and clinical developments in neuromuscular medicine. These focused sessions provide opportunities for scientific exchange, innovation, and collaboration within the global neuromuscular community.
8 July 2026
Showcase Theatre ST01 – Satellos Bioscience
- Date: Wednesday, 8 July
- Time: 16:05 - 16:20
- Title: From Regeneration to Function: Advancing Muscle Repair with SAT-3247
- Presenter: Wildon Farwell, MD, MPH, Satellos Chief Medical Officer
- Description: Satellos Bioscience operates on a simple but powerful premise: in muscular dystrophies the problem isn’t only muscle damage, but also the lack of effective muscle regeneration and repair. In this showcase theater, Satellos Chief Medical Officer Dr. Wildon Farwell will discuss 1) a critical but underappreciated role of dystrophin in muscle function and degeneration, 2) our small-molecule (SAT-3247) approach to harnessing a separate, dystrophin-independent mechanism (AAK1) within satellite cells to enhance muscle regeneration, 3) our emerging data in people living with Duchenne muscular dystrophy (DMD), and 4) our clinical development program in DMD and potential utility of SAT-3247 in other muscle disorders.
Showcase Theatre ST02 – BridgeBio Pharma, Inc
- Date: Wednesday, 8 July
- Time: 16:25 - 16:40
- Title: Interim analysis from ongoing Phase 3 FORTIFY study of BBP-418 in patients with limb girdle muscular dystrophy 2I/R9 meets efficacy endpoints
- Presenter: Douglas M. Sproule, MD MSc, Chief Medical Officer, BridgeBio
- Description: FORTIFY (NCT05775848) is a randomized, double-blind, placebo-controlled Phase 3 trial. This prespecified 1-year interim analysis evaluated biochemical, functional, and safety endpoints in patients with LGMD2I/R9. The primary endpoint was the change from baseline in glycosylated αDG at 3 months; key secondary endpoints included serum creatine kinase (CK), 100-meter timed test (100MTT) velocity, and forced vital capacity (FVC). Patient reported outcomes were also assessed.
9 July 2026
Showcase Theatre ST03 – Lupin Neurosciences Specialty & ICNMD 2026 Scientific Theatre
- Date: Thursday, 9 July
- Time: 16:05 - 16:20
- Title: Channelopathies in childhood: the mosaic of myotonia
- Presenter: Dr. Pinki Munot, Department of Neurology, Great Ormond Street Hospital (GOSH), NHS Foundation Trust, London, UK
- Description: This session discusses the physiological and clinical attributes of skeletal muscle channelopathies. It explains the heterogeneity of non-dystrophic myotonia in children, including symptoms, patient impact, disease burden, and clinical management.